Pan Jiang, Hongyu Lu, Yichun Jiang, Fanglan Li, Yan Wen, Changshan Wang, Wenfeng Wu, Feng Xu
{"title":"Association between the triglyceride-glucose index and mortality in the asthma population.","authors":"Pan Jiang, Hongyu Lu, Yichun Jiang, Fanglan Li, Yan Wen, Changshan Wang, Wenfeng Wu, Feng Xu","doi":"10.1016/j.rmed.2025.107989","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the relationship between the triglyceride-glucose (TyG) index and mortality in individuals with asthma, given the inconclusive evidence linking metabolic dysfunction to asthma outcomes.</p><p><strong>Research design and methods: </strong>We analyzed data from 5,985 adults with asthma from the National Health and Nutrition Examination Survey (NHANES) 2001-2018. We used multivariable weighted Cox regression, smoothing curve fitting, survival curve analysis, and subgroup analysis to assess the correlation between the TyG index and survival rates.</p><p><strong>Results: </strong>A higher TyG index significantly correlated with increased all-cause mortality in asthmatics. Adjusted hazard ratios (HR) for higher TyG index categories (compared to TyG < 8) were: 1.69 (95% CI: 1.28, 2.24, p < 0.001) for 8 ≤ TyG < 9, 2.04 (95% CI: 1.51, 2.76, p < 0.001) for 9 ≤ TyG < 10, and 2.94 (95% CI: 2.03, 4.28, p < 0.001) for TyG ≥ 10. Restricted cubic spline analysis revealed a nonlinear relationship between the TyG score and mortality. Kaplan-Meier curves showed higher TyG indexes associated with greater mortality risk.</p><p><strong>Conclusions: </strong>The TyG index is a significant predictor of mortality in asthma patients, highlighting its potential for risk stratification. Incorporating the TyG index into clinical assessments could improve monitoring and management. Future research should investigate interventions targeting the TyG index to enhance survival and quality of life in asthma patients.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"107989"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rmed.2025.107989","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To explore the relationship between the triglyceride-glucose (TyG) index and mortality in individuals with asthma, given the inconclusive evidence linking metabolic dysfunction to asthma outcomes.
Research design and methods: We analyzed data from 5,985 adults with asthma from the National Health and Nutrition Examination Survey (NHANES) 2001-2018. We used multivariable weighted Cox regression, smoothing curve fitting, survival curve analysis, and subgroup analysis to assess the correlation between the TyG index and survival rates.
Results: A higher TyG index significantly correlated with increased all-cause mortality in asthmatics. Adjusted hazard ratios (HR) for higher TyG index categories (compared to TyG < 8) were: 1.69 (95% CI: 1.28, 2.24, p < 0.001) for 8 ≤ TyG < 9, 2.04 (95% CI: 1.51, 2.76, p < 0.001) for 9 ≤ TyG < 10, and 2.94 (95% CI: 2.03, 4.28, p < 0.001) for TyG ≥ 10. Restricted cubic spline analysis revealed a nonlinear relationship between the TyG score and mortality. Kaplan-Meier curves showed higher TyG indexes associated with greater mortality risk.
Conclusions: The TyG index is a significant predictor of mortality in asthma patients, highlighting its potential for risk stratification. Incorporating the TyG index into clinical assessments could improve monitoring and management. Future research should investigate interventions targeting the TyG index to enhance survival and quality of life in asthma patients.
期刊介绍:
Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants.
Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.